Synopsis: A routine store-count disclosure shows Zota Health Care’s Davaindia pharmacy chain added 246 net new stores in the June 2026 quarter, taking the total network past 2,825 outlets. The expansion pace is genuinely impressive, but it arrives against a backdrop of widening losses, rising debt and a shrinking promoter stake that retail shareholders should weigh alongside the store count headline.
A leading generic pharmacy retail chain operator informed stock exchanges of its Davaindia store count for the first quarter of FY27, reporting that the network grew from 2,579 stores as on 31 March 2026 to 2,825 stores as on 30 June 2026, a net addition of 246 outlets after accounting for closures and relocations.
With a market capitalisation of around Rs. 4,958.35 crore, the shares of Zota Health Care Limited were trading at Rs. 1,431.10 per share, up 1.01 marginally from its previous closing price of Rs. 1,416.80 apiece.
Store Count Update
The company opened 264 new Davaindia stores during the quarter while closing or relocating 18, split across its two operating formats. Company-owned, company-operated stores, run through wholly owned subsidiary Davaindia Health Mart Limited, grew from 1,656 to 1,855, a net addition of 199 outlets. Franchisee-owned, franchisee-operated stores grew more modestly, from 923 to 970, a net addition of 47 outlets after 16 closures.
The tilt toward the COCO format is worth noting, since company-owned stores require Zota to fund real estate, inventory and staffing costs directly, unlike the asset-light franchise model where much of that capital comes from franchise partners.
Why the Store Count Alone Does Not Tell the Full Story
Retail investors reading a 9.5 percent quarterly jump in store count as an unambiguous positive should pause and look at what has been funding this expansion. Zota’s total borrowings climbed from Rs. 95 crore in FY24 to Rs. 140 crore in FY25 and further to Rs. 181 crore by September 2025, a pace of debt accumulation that has run well ahead of revenue growth over the same period. Operating cash flow turned sharply negative in FY25, at roughly negative Rs. 50 crore, meaning the core business consumed cash even before accounting for the capital spent opening new stores.
Return on equity over the last three years has averaged negative 24 percent, and return on capital employed sits at negative 17 percent for the latest reported year, both signs that the capital being deployed into store openings has not yet translated into profitable returns.
The company’s own disclosures paint a two-sided picture. Management told investors at its late-May earnings call that FY26 revenue rose 83.86 percent year-on-year to Rs. 538.65 crore, with EBITDA turning positive, a genuine milestone for a business that had been running operating losses in the prior year.
At the same time, quarterly net losses have been widening rather than narrowing on a year-on-year basis through most of FY26, and the stock trades at more than 12 times its book value despite the negative return profile, a combination that leaves little margin of safety if store-level economics take longer than expected to mature. Promoter holding has also fallen steadily, from 68.12 percent in early 2023 to 50.64 percent by December 2025, a trend worth tracking even though promoter selling can reflect a range of motives beyond a negative view on the business.
What This Means for Retail Investors
None of this means the Davaindia growth story is without merit. Generic pharmacy retail is a genuine structural opportunity in India, and a company scaling its store count by close to 250 outlets in a single quarter is demonstrating real execution capability on the ground. The more useful question for shareholders is not whether the stores are opening, since that part is clearly happening, but whether each new COCO store is being funded sustainably and reaching profitability within a reasonable timeframe, details that are not visible in a store-count filing and are better assessed through the company’s unit economics disclosures in its investor presentations and earnings calls rather than the headline expansion number alone.
Business Overview
Zota Health Care Limited, headquartered in Surat, is a pharmaceutical company operating across domestic marketing, exports and retail pharmacy verticals, with its Davaindia chain positioned as one of India’s largest private-sector generic pharmacy networks. The company also exports pharmaceutical, ayurvedic and nutraceutical products to markets across Asia, Africa, Russia and Latin America through its Sachin SEZ manufacturing facility. For FY26, the company reported consolidated revenue of Rs. 538.65 crore, up sharply from the prior year, as the retail pharmacy business scaled toward becoming the company’s dominant revenue driver.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
